Promising news?

Second Parkinson's Group in Trial Receives ISCO's Neural Stem Cell Therapy

Here’s their 6 month results from the first group of patients:

“Six months after receiving 30 million ISC-hpNSCs, patients in the first trial group showed a 24 percent reduction in their OFF time — a period when levodopa therapy begins to fail and Parkinson’s symptoms return. The therapy extended levodopa’s period of action without dyskinesia — known as ON time — by 19 percent.

All patients improved their mood, with an average increase of 35 % in the Beck Depression Inventory and 33 % in the Parkinson’s Disease Quality of Life Score-39 (PDQ-39). They also improved or retained their cognitive abilities, with an average improvement of 14% in the Cognitive Impairment dimension of the PDQ-39.”